Hepatocellular carcinoma
Conditions
Interventions
TACE treatment after bevacizumab biological analog combined with cedilimumab:None
TACE followed by bevacizumab biosimilars combined with sindelizumab:None
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years old, gender unlimited. 2.Confirmed by histology / cytology or clinical diagnosis (in accordance with the guidelines for the diagnosis and treatment of primary liver cancer (2024 version)) Standard) of unresectable hepatocellular carcinoma. 3.HBV related (HBsAg positive or HBV DNA positive), viral load = 12 weeks. 10. It is planned that TACE treatment after bevacizumab biological analog combined with cedilimumab will be carried out soon or TACE followed by combination therapy. First combined and then TACE treatment: first received cindilimab (200mg, i.v., day 1) combined Bevacizumab biosimilar (15mg/kg, i.v., day 1) treatment (this is from cycle 1 After completing the first cycle of combination therapy, it must be completed within 3 weeks (i.e. before the beginning of the second cycle) First TACE treatment. TACE before combination therapy: first receive the first TACE treatment. After TACE, it must be within 2 weeks The first systemic treatment was started, i.e., the infusion of sindelimumab (200mg, i.v.) combined with bevacizumab Analogues (15mg/kg, i.v.). 11.Voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Pathological types such as intrahepatic cholangiocarcinoma or mixed liver cancer 2. Main portal vein tumor thrombus (VP4) or inferior vena cava tumor thrombus 3.History of hepatic encephalopathy or liver transplantation 4.Presence of CNS metastases 5.Severe cardiovascular and cerebrovascular disease, active infection and other comorbidities 6.Active autoimmune disease or long-term use of immunosuppressants 7.Allergy to study drug or its components 8.Pregnant or lactating women 9.Other circumstances that the investigator believes are not suitable for participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Objective response rate;Disease control rate;Duration of mitigation; | — |
Countries
China
Contacts
Public ContactEnqiang Chen
West China Hospital, Sichuan University
Outcome results
None listed